Phio Pharmaceuticals Corp. (PHIO) has been given the go-ahead by the Safety Monitoring Committee to proceed with dose escalation in its phase Ib clinical trial of PH-762.
PH-762, the company's lead drug candidate works by silencing the PD-1 gene implicated in various forms of skin cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com